We look at drug development differently.
ENDECE’s library of proprietary compounds was invented to stop disease by up-regulating genes within biological pathways to stimulate biological response associated with therapeutic targets. Compounds within ENDECE’s library vary greatly in terms of their biological activity. Key candidates identified to date include potential therapeutics for demyelinating diseases such as, neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), osmotic demyelination syndrome (ODS), and Alzheimer’s disease (cognition).
Diseases with few if any treatment options .